ASH Data Raise Hopes For Ibrutinib As Single Agent, Chemo-Free Option In CLL
This article was originally published in The Pink Sheet Daily
Executive Summary
With the latest response, safety and durability data creating a buzz at the American Society of Hematology, Pharmacyclics CMO Lori Anne Kunkel discusses possibility for accelerated approval in a high-risk type of chronic lymphocytic leukemia. Drug also shows promise in trials of a genetic subtype of diffuse large B-cell lymphoma and mantle cell lymphoma.
You may also be interested in...
Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.